Bezafibrate对大鼠高脂血症和脂肪肝形成的影响  

Effect of bezafibrate on the development of fatty Liver with hyperlipidemia in rats chronically fed with high fat diet

作　　者：范建高[1,2] 曾民德[1,2] 李继强[1,2] 邱德凯 李超群[1,2] 李蓉蓉[1,2] 

机构地区：[1]上海第二医科大学消化科 [2]上海市消化疾病研究所

出　　处：《胃肠病学和肝病学杂志》1999年第2期100-102,共3页Chinese Journal of Gastroenterology and Hepatology

摘　　要：目的探讨以降低甘油三酯为主的血脂调整药对高脂血症脂肪肝的防治作用。方法观察Ｂｅｚａｆｉｂｒａｔｅ对高脂饮食诱发Ｗｉｓｔａｒ大鼠高脂血症和脂肪肝形成的影响（治疗组，ｎ＝８），并设模型组和正常饮食组作对照。结果与正常组相比，模型组血脂和肝匀浆脂肪含量均显著升高，肝组织学呈中至重度脂肪变。与模型组相比，治疗组血清甘油三酯和总胆固醇显著下降，但血清转氨酶和肝匀浆脂质含量却呈升高趋势，肝脏病理学变化与模型组基本相近。结论Ｂｅｚａｆｉｂｒａｔｅ虽可显著降低高脂饮食诱发的高脂血症，但对肝内脂肪沉积并无防治作用。Aim To explore the effect of serum lipid adjustment drugs with decreasing serum triglyceride mainly on the development of hyperlipidemia and fatty liver. Methods We observed the effect of Bezafibrate on the development of hyperlipidemia and fatty liver in Wistar rats chronically fed with high fat diet(the therapeutic group,n=8),and the model group and normal diet group as control. Results The content of triglyceride and total cholesterol both in serum and liver in the model group were significantly higher than those in normal group,furtheremore,moderate and severe hepatic steatosis in model group were observed.The level of serum triglyceride and total cholesterol in the therapeutic group were significantly lower than those in model group;But both serum aminotransferase activity and the content of hepatic triglyceride in the therapeutic group were slightly higher than those in the model group,moreover,the difference of changes of hepatic pathology between two groups were obviousless. Conclusions Although Bezafibrate may decrease obviously the serum lipid induced by high fat diet,it has no effect on the prevention and treatment of fatty liver.

关 键 词：BEZAFIBRATE 高脂血症 脂肪肝 血脂调整药 

分 类 号：R972.6[医药卫生—药品] R589.201[医药卫生—药学]